ArticleReproductive medicine and biology
Positive and Negative Aspects of Public Insurance Coverage on ART With Respect to Multiple Gestation in Japan.
Article in Reproductive medicine and biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study examined whether the application of public insurance on assisted reproductive technology in Japan was associated with changes in the incidence of multiple blastocyst transfer (MBT) and subsequent multiple pregnancies (MP). Methods: A total of 2764 blastocyst transfer cycles performed at IVF Osaka Clinic from the pre-insurance period (January 2020-March 2022) were retrospectively compared with 4,326 cycles from the insurance period (April 2022-February 2025). MP was defined as two or more gestational sacs. Results: Baseline analysis showed that patients' age after insurance coverage was significantly younger with fewer previous ET attempts than pre-insurance. MBT rose from 5.8% pre-insurance to 20.1% under insurance, and MP increased from 0.7% to 2.6%, simultaneously. Insurance coverage was independently associated with a higher likelihood of MBT, an association most pronounced in the older age cohort. MBT exhibited the highest risk profile for MP. Significant upward trends in MBT and MP were observed as patients approached their final insured cycles. Conclusions: Findings suggest a correlation between insured cycle limits and clinical practice toward prioritizing per-cycle success. Although alleviating financial burden, the policy appears to be associated with increased MBT and MP, making it necessary to deliberate its impact on maternal and neonatal safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.